C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2026)

C4 Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$13.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 216.9% year-over-year to -$13.3 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 126.02% increase from a year earlier, with the FY2025 full-year figure at $19.1 million, up 126.87% from the prior year.
• Net Cash Flow eased to -$13.3 million in Q1 2026 per CCCC's latest filing, from $15.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $65.6 million in Q4 2023 and bottomed at -$36.9 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$4.6 million (2023), against an average of -$863882.4.
• Across the five-year window, Net Cash Flow slumped 287.26% in 2024 and soared 480.58% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$19.8 million in 2022, then jumped by 431.4% to $65.6 million in 2023, then tumbled by 106.33% to -$4.1 million in 2024, then surged by 480.58% to $15.8 million in 2025, then slumped by 184.39% to -$13.3 million in 2026.
• Per Business Quant, the three latest CCCC Net Cash Flow figures stand at -$13.3 million (Q1 2026), $15.8 million (Q4 2025), and -$19.3 million (Q3 2025).